Photoreceptor Preservation Induced by Intravitreal Controlled Delivery of GDNF and GDNF/melatonin in Rhodopsin Knockout Mice

Overview

Journal Mol Vis

Specialties Cell Biology
Molecular Biology
Ophthalmology

Date 2018 Dec 25

PMID 30581280

Citations 14

Authors

Cristina Garcia-Caballero

Burke Lieppman

Alicia Arranz-Romera

Irene T Molina-Martinez

Irene Bravo-Osuna

Michael Young

Petr Baranov

Rocio Herrero-Vanrell

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the potential of a poly(lactic-co-glycolic acid) (PLGA)-based slow release formulation of glial cell line-derived neurotrophic factor (GDNF) alone or in combination with melatonin to rescue photoreceptors in a mouse model of retinal degeneration.

Methods: GDNF and GDNF/melatonin-loaded PLGA microspheres (MSs) were prepared using a solid-in-oil-in-water emulsion solvent extraction-evaporation technique. A combination of PLGA and vitamin E (VitE) was used to create the microcarriers. The structure, particle size, encapsulation efficiency, and in vitro release profile of the microparticulate formulations were characterized. Microparticulate systems (non-loaded, GDNF, and GDNF/melatonin-loaded MSs) were administered intravitreally to 3-week-old rhodopsin knockout mice ( (-/-); n=7). The functional neuroprotective effect was assessed with electroretinography at 6, 9, and 12 weeks old. The rescue of the structure was determined with photoreceptor quantification at 12 weeks (9 weeks after administration of MSs). Immunohistochemistry for photoreceptor, glial, and proliferative markers was also performed.

Results: The microspheres were able to deliver GDNF or to codeliver GDNF and melatonin in a sustained manner. Intravitreal injection of GDNF or GDNF/melatonin-loaded MSs led to partial functional and structural rescue of photoreceptors compared to blank microspheres or vehicle. No significant intraocular inflammatory reaction was observed after intravitreal injection of the microspheres.

Conclusions: A single intravitreal injection of GDNF or GDNF/melatonin-loaded microspheres in the PLGA/VitE combination promoted the rescue of the photoreceptors in (-/-) mice. These intraocular drug delivery systems enable the efficient codelivery of therapeutically active substances for the treatment of retinal diseases.

Citing Articles

Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model.

Aragon-Navas A, Rodrigo M, Munuera I, Garcia-Herranz D, Subias M, Villacampa P Drug Deliv Transl Res. 2024; .

PMID: 39361228 DOI: 10.1007/s13346-024-01702-x.

A Clinical, Pharmacological, and Formulation Evaluation of Melatonin in the Treatment of Ocular Disorders-A Systematic Review.

Romeo A, Kazsoki A, Musumeci T, Zelko R Int J Mol Sci. 2024; 25(7).

PMID: 38612812 PMC: 11011996. DOI: 10.3390/ijms25073999.

Human iPSC-derived neural progenitor cells secreting GDNF provide protection in rodent models of ALS and retinal degeneration.

Laperle A, Moser V, Avalos P, Lu B, Wu A, Fulton A Stem Cell Reports. 2023; 18(8):1629-1642.

PMID: 37084724 PMC: 10444557. DOI: 10.1016/j.stemcr.2023.03.016.

Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres.

Aragon-Navas A, Rodrigo M, Garcia-Herranz D, Martinez T, Subias M, Mendez S Drug Deliv. 2022; 29(1):2357-2374.

PMID: 35904152 PMC: 9341346. DOI: 10.1080/10717544.2022.2096712.

Glial cell line-derived neurotrophic factor (GDNF) in patients with primary open-angle glaucoma and age-related cataract.

Shpak A, Guekht A, Druzhkova T, Troshina A, Gulyaeva N Mol Vis. 2022; 28:39-47.

PMID: 35656168 PMC: 9108012.

References

Lockshin R, Williams C . PROGRAMMED CELL DEATH--I. CYTOLOGY OF DEGENERATION IN THE INTERSEGMENTAL MUSCLES OF THE PERNYI SILKMOTH. J Insect Physiol. 1965; 11:123-33. DOI: 10.1016/0022-1910(65)90099-5. View

Belforte N, Moreno M, de Zavalia N, Sande P, Chianelli M, Keller Sarmiento M . Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res. 2010; 48(4):353-64. DOI: 10.1111/j.1600-079X.2010.00762.x. View

Ortin-Martinez A, Valiente-Soriano F, Garcia-Ayuso D, Alarcon-Martinez L, Jimenez-Lopez M, Bernal-Garro J . A novel in vivo model of focal light emitting diode-induced cone-photoreceptor phototoxicity: neuroprotection afforded by brimonidine, BDNF, PEDF or bFGF. PLoS One. 2014; 9(12):e113798. PMC: 4252057. DOI: 10.1371/journal.pone.0113798. View

Jiang C, Moore M, Zhang X, Klassen H, Langer R, Young M . Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007; 13:1783-92. View

Koriyama Y, Sugitani K, Ogai K, Kato S . Heat shock protein 70 induction by valproic acid delays photoreceptor cell death by N-methyl-N-nitrosourea in mice. J Neurochem. 2014; 130(5):707-19. DOI: 10.1111/jnc.12750. View

Del Rio P, Irmler M, Arango-Gonzalez B, Favor J, Bobe C, Bartsch U . GDNF-induced osteopontin from Müller glial cells promotes photoreceptor survival in the Pde6brd1 mouse model of retinal degeneration. Glia. 2011; 59(5):821-32. DOI: 10.1002/glia.21155. View

Andrieu-Soler C, Aubert-Pouessel A, Doat M, Picaud S, Halhal M, Simonutti M . Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol Vis. 2005; 11:1002-11. View

Portera-Cailliau C, Sung C, Nathans J, Adler R . Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A. 1994; 91(3):974-8. PMC: 521436. DOI: 10.1073/pnas.91.3.974. View

Del Amo E, Urtti A . Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008; 13(3-4):135-43. DOI: 10.1016/j.drudis.2007.11.002. View

10.

Ma J, Kabiel M, Tucker B, Ge J, Young M . Combining chondroitinase ABC and growth factors promotes the integration of murine retinal progenitor cells transplanted into Rho(-/-) mice. Mol Vis. 2011; 17:1759-70. PMC: 3133841. View

11.

Baba K, Benleulmi-Chaachoua A, Journe A, Kamal M, Guillaume J, Dussaud S . Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal. 2013; 6(296):ra89. PMC: 3867265. DOI: 10.1126/scisignal.2004302. View

12.

Herrero-Vanrell R, Bravo-Osuna I, Andres-Guerrero V, Vicario-de-la-Torre M, Molina-Martinez I . The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Prog Retin Eye Res. 2014; 42:27-43. DOI: 10.1016/j.preteyeres.2014.04.002. View

13.

Wiechmann A, Summers J . Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues. Prog Retin Eye Res. 2008; 27(2):137-60. DOI: 10.1016/j.preteyeres.2007.10.001. View

14.

Hardeland R . Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005; 27(2):119-30. DOI: 10.1385/endo:27:2:119. View

15.

Checa-Casalengua P, Jiang C, Bravo-Osuna I, Tucker B, Molina-Martinez I, Young M . Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release. 2011; 156(1):92-100. DOI: 10.1016/j.jconrel.2011.06.023. View

16.

Schimel A, Abraham L, Cox D, Sene A, Kraus C, Dace D . N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation. Am J Pathol. 2011; 178(5):2032-43. PMC: 3081196. DOI: 10.1016/j.ajpath.2011.01.036. View

17.

Tosini G, Menaker M . Circadian rhythms in cultured mammalian retina. Science. 1996; 272(5260):419-21. DOI: 10.1126/science.272.5260.419. View

18.

Komeima K, Rogers B, Lu L, Campochiaro P . Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci U S A. 2006; 103(30):11300-5. PMC: 1544081. DOI: 10.1073/pnas.0604056103. View

19.

Samples J, Krause G, Lewy A . Effect of melatonin on intraocular pressure. Curr Eye Res. 1988; 7(7):649-53. DOI: 10.3109/02713688809033192. View

20.

Hussain R, Ciulla T . Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2015; 16(3):365-74. DOI: 10.1517/14712598.2016.1131265. View